Ratings Pfizer, Inc. Deutsche Boerse AG

Equities

PFE

US7170811035

Market Closed - Deutsche Boerse AG Other stock markets 14:48:29 2024-05-17 EDT			5-day change	1st Jan Change
26.3 ^EUR	-1.22%		+0.79%	+0.75%

05-17	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE
05-17	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
The company is one of the best yield companies with high dividend expectations.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
One of the major weak points of the company is its financial situation.
The company's enterprise value to sales, at 3.65 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PFIZER, INC.	+0.75%	164B	-
ELI LILLY AND COMPANY	+32.09%	694B	C+
NOVO NORDISK A/S	+29.39%	593B	B
JOHNSON & JOHNSON	-1.34%	371B	C+
MERCK & CO., INC.	+20.34%	331B	B-
ABBVIE INC.	+7.39%	290B	C+
ASTRAZENECA PLC	+14.25%	239B	B+
ROCHE HOLDING AG	-3.03%	209B	A+
NOVARTIS AG	+10.02%	209B	B-
AMGEN INC.	+8.49%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes